According to filings with the U.S. Securities and Exchange Commission, Halda Therapeutics is raising up to $126,471,316.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Scott Phillips played a…
Six premier investors join syndicate for Series B extension to fund clinical trials of RIPTAC drug candidates for prostate cancer and breast cancer Initial clinical trial for first-in-class RIPTAC therapeutic in patients with metastatic castration-resistant…
According to filings with the U.S. Securities and Exchange Commission, Halda Therapeutics is raising up to $36,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Scott Phillips played a…